title: Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial.
abstract: BACKGROUND
  Hot flashes can be troublesome, especially when hormonal therapy is contraindicated. Preliminary data have suggested that newer antidepressants, such as venlafaxine, can diminish hot flashes. We undertook a double-blind, placebo-controlled, randomised trial to assess the efficacy of venlafaxine in women with a history of breast cancer or reluctance to take hormonal treatment because of fear of breast cancer.
  
  
  METHODS
  Participants were assigned placebo (n=56) or venlafaxine 37.5 mg daily (n=56), 75 mg daily (n=55), or 150 mg daily (n=54). After a baseline assessment week, patients took the study medication for 4 weeks. All venlafaxine treatment started at 37.5 mg daily and gradually increased in the 75 mg and 150 mg groups. Patients completed daily hot-flash questionnaire diaries. The primary endpoint was average daily hot-flash activity (number of flashes and a score combining number and severity). Analyses were based on the women who provided data throughout the baseline and study weeks.
  
  
  RESULTS
  191 patients had evaluable data for the whole study period (50 placebo, 49 venlafaxine 37.5 mg, 43 venlafaxine 75 mg, 49 venlafaxine 150 mg). After week 4 of treatment, median hot flash scores were reduced from baseline by 27% (95% CI 11-34), 37% (26-54), 61% (50-68), and 61% (48-75) in the four groups. Frequencies of some side-effects (mouth dryness, decreased appetite, nausea, and constipation) were significantly higher in the venlafaxine 75 mg and 150 mg groups than in the placebo group.
  
  
  CONCLUSIONS
  Venlafaxine is an effective non-hormonal treatment for hot flashes, though the efficacy must be balanced against the drug's side-effects. Confirmation of the results of this 4-week study awaits the completion of three ongoing randomised studies to assess the effects of other related antidepressants for the treatment of hot flashes.
authors.affiliation: Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA. cloprinzi@mayo.edu
authors.forename: C L
authors.initials: CL
authors.lastname: Loprinzi
authors.forename: J W
authors.initials: JW
authors.lastname: Kugler
authors.forename: J A
authors.initials: JA
authors.lastname: Sloan
authors.forename: J A
authors.initials: JA
authors.lastname: Mailliard
authors.forename: B I
authors.initials: BI
authors.lastname: LaVasseur
authors.forename: D L
authors.initials: DL
authors.lastname: Barton
authors.forename: P J
authors.initials: PJ
authors.lastname: Novotny
authors.forename: S R
authors.initials: SR
authors.lastname: Dakhil
authors.forename: K
authors.initials: K
authors.lastname: Rodger
authors.forename: T A
authors.initials: TA
authors.lastname: Rummans
authors.forename: B J
authors.initials: BJ
authors.lastname: Christensen
mesh_terms: D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms; D003511:Cyclohexanols / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D019584:Hot Flashes / Q000188:drug therapy*; D006801:Humans; D000069470:Venlafaxine Hydrochloride
chemical_list: D018687:Antidepressive Agents, Second-Generation; D003511:Cyclohexanols; D000069470:Venlafaxine Hydrochloride